Herceptin, Roche | search
Click here to view Herceptin, Roche news from 60+ newspapers.
Bookmark or Share- Roche | Herceptin SC / Herceptin Hylecta (trastuzumab hyaluronidase)Herceptin was the first HER2-targeted therapy for breast cancer. It is a monoclonal antibody that binds to HER2 receptors present on the surface of HER2-positive tumour cells, blocking them from receiving growth signals and flagging them for destruction by the immune system.
- herceptin - HER2+ Breast & Stomach Cancer Treatment OptionHERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) is approved for the treatment of adults with early-stage breast cancer that is H uman E pidermal growth factor R eceptor 2 -positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes.
- Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk | A HER2 ...Learn about Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk), a treatment option for eligible patients with HER2-positive breast cancer. See Full Safety, including most serious side effects, for more information.
- Herceptin (trastuzumab) - RocheHerceptin was the first HER2-targeted therapy for breast cancer. It is a monoclonal antibody that binds to HER2 receptors present on the surface of HER2-positive tumour cells, blocking them from receiving growth signals and flagging them for destruction by the immune system.
- HERCEPTIN - RochePatients treated with Herceptin are at increased risk of developing congestive heart failure (CHF) (New York Heart Association [NYHA] Class II-IV) or asymptomatic cardiac dysfunction. These events have been observed in patients receiving Herceptin therapy alone or in combination with taxane following anthracycline (doxorubicin or epirubicin)–
More
